
Sasja F Mulder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6256498/publications.pdf Version: 2024-02-01



SASIA E MULDER

#	Article	IF	CITATIONS
1	Exposureâ€ŧoxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer. International Journal of Cancer, 2022, 150, 308-316.	5.1	8
2	Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer. BMC Cancer, 2022, 22, 228.	2.6	11
3	Roles of general practitioners in shared decisionâ€making for patients with cancer: A qualitative study. European Journal of Cancer Care, 2022, 31, e13594.	1.5	3
4	Cardiovascular disease in testicular cancer survivors: Identification of risk factors and impact on quality of life Journal of Clinical Oncology, 2022, 40, 12070-12070.	1.6	1
5	Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. Clinical Genitourinary Cancer, 2021, 19, 274.e1-274.e16.	1.9	12
6	The relationship between sunitinib exposure and both efficacy and toxicity in realâ€world patients with renal cell carcinoma and gastrointestinal stromal tumour. British Journal of Clinical Pharmacology, 2021, 87, 326-335.	2.4	18
7	Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study. BMC Gastroenterology, 2021, 21, 67.	2.0	2
8	Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites. Cancer Chemotherapy and Pharmacology, 2021, , 1.	2.3	2
9	Hospital-specific probability of cystectomy affects survival from muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 935.e9-935.e16.	1.6	2
10	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. Oncologist, 2020, 25, e1509-e1515.	3.7	10
11	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (<scp>DIET</scp> Study). Clinical Pharmacology and Therapeutics, 2019, 106, 1076-1082.	4.7	26
12	A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?. Journal of Clinical Oncology, 2019, 37, 4564-4564.	1.6	2
13	Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. European Urology, 2018, 74, 257-260.	1.9	65
14	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. Targeted Oncology, 2018, 13, 641-648.	3.6	10
15	Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane Journal of Clinical Oncology, 2018, 36, 1062-1062.	1.6	Ο
16	Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients Journal of Clinical Oncology, 2018, 36, 4572-4572.	1.6	0
17	Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. British Journal of Clinical Pharmacology, 2017, 83, 2195-2204.	2.4	61
18	Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?. Acta Oncológica, 2016, 55, 444-448.	1.8	6

Sasja F Mulder

#	Article	IF	CITATIONS
19	Phase 2 Study of Lutetium 177–Labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. European Urology, 2016, 69, 767-770.	1.9	57
20	Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. Anticancer Research, 2015, 35, 5601-6.	1.1	2
21	Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens. Frontiers in Immunology, 2014, 5, 191.	4.8	71
22	Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study. BMC Cancer, 2014, 14, 219.	2.6	53
23	Humoral and cellular immune response after influenza vaccination in patients with postcancer fatigue and patients with chronic fatigue syndrome Journal of Clinical Oncology, 2012, 30, 9070-9070.	1.6	Ο
24	The complexity of sunitinib dosing in renal cell cancer patients. Translational Andrology and Urology, 2012, 1, 194-6.	1.4	0
25	Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination. Clinical Cancer Research, 2011, 17, 4541-4549.	7.0	28
26	Do the Results of the New Trials Change the Standard Treatment of Metastatic Renal Cell Cancer?. Oncology Research and Treatment, 2007, 30, 260-264.	1.2	5